globe usa magnifying-glass checkbox g-plus rss youtube fb-round connect-with-us-in connect-with-us-twitter youtube2 facebook linkedin twitter
The website you have requested may contain information on products or uses of such products that are not approved in your country. For specific product and country information please contact Medinol

The PREHAMI Registry

  • A prospective single-center registry evaluating the outcomes of patients with high-risk acute MI who underwent PCI with the NIRxcell stent
  • 129 patients enrolled in Rome, Italy
  • Patients undergoing acute MI (STEMI and non-STEMI)
  • Primary endpoint: MACE in-hospital and at 12 months
  • Result: The in-hospital MACE was 5.4%, at 6 months it was 13.3% and 17.3% at 12 months. The 12 months rate of TVR was 4.6%
NIRxcell Performance in High Risk AMI Pateints